A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
Severe constipation, painful bloating, vomiting, or inability to pass stool or gas
These medications were initially created to treat type 2 diabetes and have been extensively researched for several decades
At The WellSpa, we recognize that patient convenience is crucial, hence we appreciate that Semaglutide GLP-1 offers a once-weekly dosage regimen that may suit some patients more than the daily dosage required for liraglutide
Ozempic is an FDA-approved prescription medication for the treatment of type 2 diabetes alongside diet and exercise